After years of shortages, Merck announces plans for a new factory for an old lifesaving drug
Four years after Sanofi left them as a popular bladder cancer drug’s only producer, Merck is investing in a new facility that could help ameliorate the widespread shortages that patients, doctors and manufacturers have faced for nearly a decade.
Merck said they will build a new plant at their Durham, NC vaccine manufacturing center to produce BCG, an immunotherapy that has been used for decades to treat bladder cancer. The facility won’t be an immediate solution — Merck said it will take 5 to 6 years to construct and even then, the batches will only grow gradually — but the company, one of the world’s largest producers of vaccines, said it will eventually triple their current production and meet demand.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.